Keqing LI Li

Dr. Keqing LI Li


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Journal of Psychiatric Research
Verified
Journal Article
Open access
HLHuafang Li
Huafang Li
CYChen Yao
Chen Yao
JSJianguo Shi
Jianguo Shi
FYFude Yang
Fude Yang
SQShuguang Qi
Shuguang Qi
NGNiufan Gu
Niufan Gu
This randomized, double-blind study compared the efficacy and safety of blonanserin and risperidone to treat Chinese schizophrenia patients aged ≥18 and < 65 years. Patients with Positive and Negative Syndrome Scale (PANSS) total scores ≥70 and ≤ 120 were randomized to receive blonanserin or risperidone using a gradual dose-titration method (blonanserin tablets: 8-24 mg/day; risperidone tablets: 2-6 mg/day), twice daily. Treatment populations consisted of 128 blonanserin-treated patients and 133 risperidone-treated patients. Intention-to-treat analysis was performed using the last observation carried forward method. Reductions of PANSS total scores by blonanserin and risperidone treatment were -30.59 and -33.56, respectively. Risperidone treatment was associated with elevated levels of serum prolactin (67.16% risperidone versus 52.31% blonanserin) and cardiac-related abnormalities (22.39% risperidone versus 12.31% blonanserin), and blonanserin patients were more prone to extrapyramidal side effects (48.46% blonanserin versus 29.10% risperidone). In conclusion, blonanserin was as effective as risperidone for the treatment of Chinese patients with schizophrenia. The overall safety profiles of these drugs are comparable, although blonanserin was associated with a higher incidence of EPS and risperidone was associated with a higher incidence of prolactin elevation and weight gain. Thus, blonanserin is useful for the treatment of Chinese schizophrenia patients.

29 November 2022 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
MWMin Wen
Min Wen
ZDZhen Dong
Zhen Dong
LZLili Zhang
Lili Zhang
BLBing Li
Bing Li
YZYunshu Zhang
Yunshu Zhang
KLKeqing LI Li
Keqing LI Li
Background: Eye movement is critical for obtaining precise visual information and providing sensorimotor processes and advanced cognitive functions to the brain behavioral indicator. Methods: In this article, we present a narrative review of the eye-movement paradigms (such as fixation, smooth pursuit eye movements, and memory-guided saccade tasks) in major depression. Results: Characteristics of eye movement are considered to reflect several aspects of cognitive deficits regarded as an aid to diagnosis. Findings regarding depressive disorders showed differences from the healthy population in paradigms, the characteristics of eye movement may reflect cognitive deficits in depression. Neuroimaging studies have demonstrated the effectiveness of different eye movement paradigms for MDD screening. Conclusion: Depression can be distinguished from other mental illnesses based on eye movements. Eye movement reflects cognitive deficits that can help diagnose depression, and it can make the entire diagnostic process more accurate.

9 January 2018 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
PDF file
XLXiao Liu
Xiao Liu
JLJitao Li
Jitao Li
CGChunmei Guo
Chunmei Guo
HWHongli Wang
Hongli Wang
YSYaxin Sun
Yaxin Sun
TSTian-Mei Si
Tian-Mei Si
Cognitive dysfunction constitutes an essential component in schizophrenia for its early presence in the pathophysiology of the disease and close relatedness to life quality of patients. To develop effective treatment of cognitive deficits, it is important to understand their neurobiological causes and to identify potential therapeutic targets. In this study, adopting repeated MK-801 treatment as an animal model of schizophrenia, we investigated whether antipsychotic drugs, olanzapine and haloperidol, can reverse MK-801-induced cognitive deficits and how the reversal processes recruited proteins involved in glutamate neurotransmission in rat medial prefrontal cortex (mPFC) and hippocampus. We found that low-dose chronic MK-801 treatment impaired object-in-context recognition memory and reversal learning in the Morris water maze, leaving reference memory relatively unaffected, and that these cognitive deficits can be partially reversed by olanzapine, not haloperidol, treatment. At the molecular level, chronic MK-801 treatment resulted in the reduction of multiple N-methyl-D-aspartate (NMDA) receptor subunits in rat mPFC and olanzapine, not haloperidol, treatment restored the levels of GluN1 and phosphorylated GluN2B in this region. Taken together, MK-801-induced cognitive deficits may be associated with region-specific changes in NMDA receptor subunits and the reversal of specific NMDA receptor subunits may underlie the cognition-enhancing effects of olanzapine.

1 December 2011 in Journal of Affective Disorders
Verified
Journal Article
Open access
WSWenhua Sang
Wenhua Sang
YLYihan Li
Yihan Li
LSLiang Su
Liang Su
FYFuzhong Yang
Fuzhong Yang
WWWenyuan Wu
Wenyuan Wu
KLKeqing LI Li
Keqing LI Li
Background: The relationship between major depressive disorder (MDD) and dysthymia, a form of chronic depression, is complex. The two conditions are highly comorbid and it is unclear whether they are two separate disease entities. We investigated the extent to which patients with dysthymia superimposed on major depression can be distinguished from those with recurrent MDD. Methods: We examined the clinical features in 1970 Han Chinese women with MDD (DSM-IV) between 30 and 60 years of age across China. Logistic regression was used to determine the association between clinical features of MOD and dysthymia and between dysthymia and disorders comorbid with major depression. Results: The 354 cases with dysthymia had more severe MOD than those without, with more episodes of MDD and greater co-morbidity for anxiety disorders. Patients with dysthymia had higher neuroticism scores and were more likely to have a family history of MDD. They were also more likely to have suffered serious life events. Limitations: Results were obtained in a clinically ascertained sample of Chinese women and may not generalize to community-acquired samples or to other populations. It is not possible to determine whether the associations represent causal relationships. Conclusions: The additional diagnosis of dysthymia in Chinese women with recurrent MOD defines a meaningful and potentially important subtype. We conclude that in some circumstances it is possible to distinguish double depression from recurrent MDD. (C) 2011 Elsevier B.V. All rights reserved.

3 July 2023 in Psychopharmacology
Verified
Journal Article
Open access
PDF file
SWSiming Wang
Siming Wang
QCQihan Cai
Qihan Cai
LXLu Xu
Lu Xu
YSYanan Sun
Yanan Sun
MWMengmeng Wang
Mengmeng Wang
ZNZhi-Yu Ni
Zhi-Yu Ni
Rationale: The management of depression continues to be challenging despite the variety of available antidepressants. Herbal medicines are used in many cultures but lack stringent testing to understand their efficacy and mechanism of action. Isoalantolactone (LAT) from Elecampane (Inula helenium) improved the chronic social defeat stress (CSDS)-induced anhedonia-like phenotype in mice comparable to fluoxetine, a selective serotonin reuptake inhibitor (SSRI). Objectives: Compare the effects of LAT and fluoxetine on depression-like behaviors in mice exposed to CSDS. Result: The CSDS-induced decrease in protein expression of postsynaptic density (PSD95), brain derived neurotrophic factor (BDNF), and glutamate receptor subunit-1 (GluA1) in the prefrontal cortex was restored by LAT. LAT showed robust anti-inflammatory activity and can lessen the increase in IL-6 and TNF-α caused by CSDS. CSDS altered the gut microbiota at the taxonomic level, resulting in significant changes in α- and β-diversity. LAT treatment reestablished the bacterial abundance and diversity and increased the production of butyric acid in the gut that was inhibited by CSDS. The levels of butyric acid were negatively correlated with the abundance of Bacteroidetes, and positively correlated with those of Proteobacteria and Firmicutes across all treatment groups. Conclusions: The current data suggest that, similar to fluoxetine, LAT show antidepressant-like effects in mice exposed to CSDS through the modulation of the gut-brain axis.

13 December 2012 in The Primary Care Companion For CNS Disorders
Verified
Journal Article
Closed access
CLCui Lijun
Cui Lijun
KLKeqing LI Li
Keqing LI Li
SXSun Xiuli
Sun Xiuli
CZCui Ze
Cui Ze
JQJiang Qinpu
Jiang Qinpu
LHLv Hua
Lv Hua
To investigate the sleep characteristics of a community sample of patients with 13 types of mental disorders. Subjects aged 18 years and older were sampled from the Epidemiologic Sites Survey of Mental Illness at a mental health center in Hebei Province, Baoding, China, from October 2004 to March 2005. The study group included 1,874 subjects who met the diagnostic criteria of 13 types of mental disorders according to the Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Patient Edition (major depressive disorder, panic disorder, generalized anxiety disorder, posttraumatic stress disorder, dysthymic disorder, bipolar affective disorder, somatoform disorder, obsessive-compulsive disorder, specific phobia, schizophrenia, adjustment disorder, social phobia, and alcohol abuse and dependence.) The control group included 15,117 subjects without mental disorders. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality, and the Global Assessment of Functioning (GAF) was used to assess social life function. The prevalence of sleep disorders was 11.6% in the survey respondents. The prevalence of sleep disturbances in the group with 13 types of mental disorders ranged from 19.30% to 69.92%. There was a significant difference in the prevalence of sleep disorders between the study group (48.61%) and the control group (5.55%; P < .01). The prevalence of sleep disturbance in subjects with major depressive disorder and generalized anxiety disorder was 69.92% and 58.27%, respectively. Longer sleep latency and shorter sleep duration were the most common features of low quality sleep in patients with mental disorders. There was a significant difference in sleep latency and duration in subjects with major depressive disorder (P < .01), dysthymic disorder (P < .01), and generalized anxiety disorder (P < .01) compared to control subjects. Sleep medication was used most by subjects with schizophrenia and least by those with social phobia. Daytime dysfunction was most notable in subjects with major depressive disorder. Subjects with mental disorders with sleep disorders tended to be older than those with mental disorders without sleep disorders. The prevalence of sleep disorders was higher in patients with mental disorders who were female, older, less educated, retired or farmers, and widowed. There was no relation between the severity of depression and sleep disorders. The prevalence of sleep disorders in subjects with mental disorders was high. Longer sleep latency and shorter sleep duration were the most common characteristics of low quality sleep in the patients with mental disorders and were most notable in those with depression.